Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter.

Basic & clinical pharmacology & toxicology - 1 Apr 2015

Zoto Teuta, Kilickap Saadettin, Yasar Umit, Celik Ismail, Bozkurt Atilla, Babaoglu Melih Onder

Abstract excerpt

Chemotherapy-induced nausea and vomiting (CINV) remains a major adverse effect decreasing quality of life in patients with cancer. Genetic variations among patients may be responsible for part of the lack of efficacy of anti-emetic drugs. The aim of this study was to investigate how the genetic variants of the drug transporter ABCB1 (MDR1) gene affect anti-emetic treatment with 5-HT3 receptor antagonists....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B

Share to Gene Frequency

Share to Haplotypes

Share to Neoplasms

Share to Surveys and Questionnaires

Share to Vomiting

Source

Identifiers

PMID: 25286968
DOI: 10.1111/bcpt.12334

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter.PMID 25286968Read ↗

Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.Semantic proximity Read ↗

Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.Semantic proximity Read ↗

Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.Semantic proximity Read ↗

Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonistsSemantic proximity Read ↗

Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.Semantic proximity Read ↗

Pharmacogenetics of Chemotherapy-Induced Nausea and VomitingSemantic proximity Read ↗

Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.Semantic proximity Read ↗

Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients.Semantic proximity Read ↗

A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.Semantic proximity Read ↗

Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.Semantic proximity Read ↗

Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study.Semantic proximity Read ↗

Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.